ERS/EAACI关于成人哮喘重度急性加重的声明：事实、优先事项和关键研究问题。
2020/02/11
摘要
尽管使用了有效的药物来控制哮喘，但哮喘的急性加重仍然是一个主要的健康风险，需要患者和医生采取紧急行动，防止出现住院或死亡等严重后果。此外，严重的病情恶化伴随着巨额的医疗费用，以及患者及其家人的焦虑和恐惧等心理负担。欧洲变应性反应与临床免疫学会(EAACI)和欧洲呼吸学会(ERS)成立了一个特别小组(TF)，以寻找急性加重的明确定义，并确定研究的问题和重点。该声明包括来自患者的评论，这些患者曾是特别小组的成员。
ERS/EAACI Statement on severe exacerbations in asthma in adult: facts, priorities and key research questions.
Bourdin A.et al. Eur Respir J. 2019 Aug 29.
Abstract
Despite the use of effective medications to control asthma, severe exacerbations in asthma are still a major health risk and require urgent action on the part of the patient and physician to prevent a serious outcome such as hospitalisation or death. Moreover, severe exacerbations are associated with substantial huge healthcare costs, and psychological burden including anxiety and fear for patients and their families. The European Academy of Allergy and Clinical Immunology (EAACI) and the European Respiratory Society (ERS) set up a Task Force (TF) to search for a clear definition of severe exacerbations and to also define research questions and priorities. The statement includes comments from patients who were members of the TF.
尽管使用了有效的药物来控制哮喘，但哮喘的急性加重仍然是一个主要的健康风险，需要患者和医生采取紧急行动，防止出现住院或死亡等严重后果。此外，严重的病情恶化伴随着巨额的医疗费用，以及患者及其家人的焦虑和恐惧等心理负担。欧洲变应性反应与临床免疫学会(EAACI)和欧洲呼吸学会(ERS)成立了一个特别小组(TF)，以寻找急性加重的明确定义，并确定研究的问题和重点。该声明包括来自患者的评论，这些患者曾是特别小组的成员。
（中国医科大学附属第一医院 李文扬 摘译 杨冬 审校）
（Bourdin A.et al. Eur Respir J. 2019 Aug 29.）
（Bourdin A.et al. Eur Respir J. 2019 Aug 29.）
ERS/EAACI Statement on severe exacerbations in asthma in adult: facts, priorities and key research questions.
Bourdin A.et al. Eur Respir J. 2019 Aug 29.
Abstract
Despite the use of effective medications to control asthma, severe exacerbations in asthma are still a major health risk and require urgent action on the part of the patient and physician to prevent a serious outcome such as hospitalisation or death. Moreover, severe exacerbations are associated with substantial huge healthcare costs, and psychological burden including anxiety and fear for patients and their families. The European Academy of Allergy and Clinical Immunology (EAACI) and the European Respiratory Society (ERS) set up a Task Force (TF) to search for a clear definition of severe exacerbations and to also define research questions and priorities. The statement includes comments from patients who were members of the TF.
上一篇：
全球哮喘防治创议(GINA): 25年后（Eur Respir J）
下一篇：
重度哮喘患者共患病的经济负担:一项20年的基于人群的研究
